
Researchers describe a real-world study of acoramidis use in adults with ATTR heart disease
ACO-REAL is an ongoing, prospective study designed to collect real-world information about acoramidis use in adults with transthyretin amyloid cardiomyopathy (ATTR-CM) in routine clinical practice. The study plans to enroll about 2,000 adults across 21 European countries and follow them for around 12 months. It aims to document patient characteristics, treatment patterns, and safety outcomes rather than test effectiveness in a controlled way.













